血浆NT-ProBNP对慢性心力衰竭的心功能及预后关系的临床观察被引量：2

下载PDF

导出

摘要目的探讨N-端脑钠肽前体(NT-ProBNP)与心力衰竭患者的心功能NYHA分级及左室射血分数(LVEF)的关系,研究NT-ProBNP对心力衰竭的早期诊断及治疗预后的临床价值。方法选取97例心力衰竭的患者,心功能情况按照纽约心脏病协会(NYHA)标准分级。采取电化学发光法测定NTProBNP的含量。心脏彩色超声多普勒测定左室结构和左室射血分数(LVEF),研究NT-ProBNP的变化与心功能(NYHA)分级及左室射血分数、治疗预后的关系。结果 NT-ProBNP水平与左室射血分数、6 min步行试验的数值之间呈负向关,随着NYHA心功能分级的增加,NT-ProBNP的含量升高,各组间比较有着显著差异(P<0.05),动态监测NT-ProBNP发现,治疗"有效"组心衰的患者NT-ProBNP水平与治疗前比较明显下降,而治疗"死亡"组的心衰患者在治疗后NT-ProBNP水平与治疗前比较基线下降少,甚至升高。结论 NT-ProBNP能够反映心力衰竭的心功能状态,对心力衰竭的早期诊断、治疗检测及临床预后的评估有重要价值。

作者张超

机构地区黑龙江省大庆市第四医院心内科

出处《齐齐哈尔医学院学报》 2013年第22期3303-3304,共2页 Journal of Qiqihar Medical University

关键词 N端脑钠肽前体心力衰竭心功能预后

分类号 R543.3 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1汪芳,李卫,黄洁,王莉,边文彦,庞会敏,王洋,顼志敏,李一石.血浆N末端原脑利钠肽水平对慢性心力衰竭患者长期预后的预测价值[J].中华心血管病杂志,2006,34(1):28-32. 被引量：83
2Koch M, Trapp R, Kohnle M, et al. B-type natriurtic peptide and severe heart failure at baseline predict overall mortality in incident dialysis patients. Clin Nephrol,2010,73 ( 1 ) :21.
3Girsen A, Ala-Kopsala M, Makikallio K, et al. Cardiovascular hemodynamics and umbilical artery N-terminal peptide of ProB-type natriuretic petide in human fetuses with growrh restriction. Ultrosound Obstet Gyneca1,2007 ,29 :296-303.
4Provan SA, Angel K, Odegard S, et al. The association between disease activity and NT-ProBNP in 238 patents with rheumatoid arthritis : a 10-year longitudinal study. Arthritis Res Ther, 2008,10 : R70.
5Luckenbid KN, Christenson RH, Jaffe AS, et al. Cross-reactivity of BNP,NT-ProBNP and proBNP in commercial BNP and NT-ProBNP assays: preliminary obervations from the IFCC committee for stardardiztion of markets in Cardiac damdge Clin Chem, 2008,54 : 619-20.
6Bettencourt P, Frioes F, Azevedo A, et al. Prognostic information provided by serial measurements of brain nat riuretie peptide in heart failure. Int J Cardio1,2004,93:45-48.
7Rudiger A, Fischler M, Harpesp S, Homemann T, et al. In critically ill patients B-type natriuretic peptide (BNP) and N-terminal pro- BNP levels correlate with C-reactive protein values and leukocyte counts. Int J,2008,126:28-31.

二级参考文献11

1Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department(PRIDE) study. Am J Cardiol.2005 .95 :948-954.
2Pemberton C J, Yandle TG, Radenmker MT, et al. Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Am J Physiol, 1998, 275:1200-1208.
3Mancia G. Neurohumoral activation in congestive heart failure. Am Heart J, 1990,120:1532-1537.
4Yeo KT, Wu AH, Apple FS, et aL Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta, 2003, 338: 107-115.
5Tsutsmoto T, Wada A, Maeda K, et al. Plasma brain natriuretic peptide levels as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J, 1999, 20:1799-1807.
6Omland T, Aakvaag A, Bonarjee WS,et aL Plasma brain natriuretic peptide as an indicator of left ventricular systolic dysfunction and long-term survival after acute myocardial infarction: comparion with plasma atrial natriuretic peptide and N-terminal proatria natriuretic peptide. Circulation, 1996,93 : 1963-1969.
7Mc Donagh T, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic poptide, and mortality in an urban population. Heart,2001,86:21-26.
8Squire IB, O'Brien RJ, Demme B, et al. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci,2004, 107:309-316.
9Richard MA, Nicholls GM, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin : new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation, 1998, 97 : 1921-1929.
10Bazzino O, Fuselli JJ, Botto F, et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J, 2004, 25:859-866.